Sweden · Delayed Price · Currency is SEK BioArctic AB Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw record financial results, with revenues up eightfold and Leqembi sales surpassing $500 million globally. The innovation pipeline expanded, BrainTransporter technology advanced, and new partnerships were secured, supporting a strong outlook and proposed SEK 2 per share dividend.
-
LEQEMBI demand and global approvals continue to rise, with strong financials driven by royalties, milestones, and new partnerships. U.S. and Japan sales are growing, while China is expected to recover after Q4 inventory effects. The pipeline expands with new projects and collaborations.
-
Profitable growth continues with record Q2 revenues, driven by Leqembi sales and a major Novartis partnership. Leqembi launches expand in Europe, and exidavnemab advances in clinical trials. Strong cash reserves and recurring royalties support a positive outlook.
-
Entering a growth era, the company aims for sustainable profitability by 2025, driven by expanding royalties from Leqembi, new global partnerships, and a broadened pipeline in neurodegenerative diseases. The BrainTransporter platform and selective antibody programs are set to unlock further innovation and revenue streams.
-
Q1 saw record revenues and profit, driven by major licensing deals, milestone payments, and strong Leqembi sales growth. The company expects continued profitability, expanding R&D, and further market launches, with significant progress in its pipeline and technology platforms.
Fiscal Year 2024
-
Major BMS licensing deal and surging Leqembi sales drove strong Q4 results, with recurring royalties and a robust cash position setting up for profitability in 2025. R&D investment will rise as clinical programs advance, and regulatory milestones are expected to further boost revenues.
-
Strong royalty growth from Leqembi and robust cash reserves support ongoing R&D and pipeline progress. U.S., Japan, and China sales are expanding, though U.S. growth is temporarily limited by infusion capacity. Awaiting key E.U. regulatory decision.
-
Leqembi sales are accelerating globally, with strong launches in the U.S., Japan, and China, and royalties up 7,000% year-over-year. EU approval remains pending, but profitability is expected next year even without it, and the pipeline is advancing with new clinical studies and technology agreements.